APPLICATION
ANDA204101
TYPE
ANDA
ORIGINAL APPROVAL
2014-08-18
LATEST ACTION
2024-04-02
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
RIFAMPINDiscontinued
RIFAMPIN 600MG/VIAL · INJECTABLE · INJECTION
Approval history
2024-04-02Labeling · Supplement 12 · standardAP
2024-04-02Labeling · Supplement 11 · standardAP
2021-10-26Labeling · Supplement 10 · standardAP
2020-08-25Labeling · Supplement 9 · standardAP
2020-02-11Labeling · Supplement 7 · standardAP
2020-02-11Labeling · Supplement 8 · standardAP
2020-02-11Labeling · Supplement 6 · standardAP
2014-08-18UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.